United Therapeutics (NASDAQ:UTHR) CFO Sells $5,491,700.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CFO James Edgemond sold 10,000 shares of the stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $549.17, for a total value of $5,491,700.00. Following the transaction, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,366,132.92. This trade represents a 34.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

James Edgemond also recently made the following trade(s):

• On Thursday, June 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $549.29, for a total value of $5,492,900.00.
• On Monday, June 8th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.50, for a total value of $5,475,000.00.
• On Thursday, June 4th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $546.28, for a total value of $5,462,800.00.
• On Monday, June 1st, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $547.87, for a total transaction of $5,478,700.00.
• On Thursday, May 28th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $565.63, for a total transaction of $5,656,300.00.
• On Tuesday, May 26th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $572.94, for a total transaction of $5,729,400.00.
• On Thursday, May 21st, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $564.11, for a total transaction of $5,641,100.00.
• On Monday, May 18th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $567.31, for a total transaction of $5,673,100.00.
• On Thursday, May 14th, James Edgemond sold 10,000 shares of United Therapeutics stock. The stock was sold at an average price of $574.47, for a total transaction of $5,744,700.00.
• On Monday, May 11th, James Edgemond sold 10,000 shares of United Therapeutics stock. The shares were sold at an average price of $573.03, for a total transaction of $5,730,300.00.

United Therapeutics Trading Down 2.7%

Shares of UTHR stock opened at $536.59 on Friday. The stock has a market cap of $22.78 billion, a P/E ratio of 19.81, a price-to-earnings-growth ratio of 1.80 and a beta of 0.57. The stock has a 50 day simple moving average of $565.37 and a 200 day simple moving average of $523.32. United Therapeutics Corporation has a 1 year low of $272.12 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue was down 1.6% on a year-over-year basis. During the same quarter last year, the business earned $6.63 EPS. Analysts forecast that United Therapeutics Corporation will post 26.84 EPS for the current year.

Institutional Investors Weigh In On United Therapeutics

A number of hedge funds have recently made changes to their positions in UTHR. Geneos Wealth Management Inc. increased its position in United Therapeutics by 141.7% during the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 85 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its position in United Therapeutics by 18.8% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after buying an additional 70 shares in the last quarter. Jump Financial LLC bought a new stake in shares of United Therapeutics during the second quarter worth $277,000. Cerity Partners LLC increased its holdings in shares of United Therapeutics by 77.3% during the second quarter. Cerity Partners LLC now owns 12,843 shares of the biotechnology company’s stock worth $3,691,000 after buying an additional 5,600 shares in the last quarter. Finally, Bank of Nova Scotia lifted its stake in shares of United Therapeutics by 6.9% in the 2nd quarter. Bank of Nova Scotia now owns 1,628 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 105 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

UTHR has been the topic of a number of analyst reports. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Oppenheimer boosted their target price on shares of United Therapeutics from $575.00 to $600.00 and gave the company an “outperform” rating in a research report on Thursday, February 26th. HC Wainwright upped their price target on shares of United Therapeutics from $600.00 to $660.00 and gave the stock a “buy” rating in a report on Tuesday, March 31st. Morgan Stanley set a $516.00 price target on shares of United Therapeutics in a research report on Thursday, May 7th. Finally, Jefferies Financial Group reissued a “buy” rating on shares of United Therapeutics in a research note on Monday, March 2nd. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat.com, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $619.42.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.